Home  >  News
Biotechnology
+ Font Resize -

Sanofi to invest €170 million in new vaccine production facility in France

Paris, France
Thursday, October 12, 2017, 13:00 Hrs  [IST]

Sanofi is investing €170 million to expand a vaccine manufacturing site in Val de Reuil, France. The expansion further strengthens Sanofi's position as one of the world's leading seasonal flu vaccine providers. This investment is one of several major capital expenditures Sanofi has made in recent years to improve and expand its vaccine production capacities across France, the United States and Mexico. Sanofi plans to complete the expansion by 2021, subject to relevant health authority approvals, and will begin producing vaccines in this new facility in 2022. 

The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to expand supply of VaxigripTetra to up to 70 countries in six continents. The new quadrivalent influenza vaccine contains two A strains and two B strains of influenza virus, as per World Health Organization (WHO) recommendation.

"Influenza continues be a major public health problem around the world, causing serious complications, hospitalizations and deaths, mostly for certain high-risk individuals," said David Loew, executive vice president, Sanofi, and head of Sanofi Pasteur. "As a global leader in flu vaccines, this expansion reinforces Sanofi Pasteur's ability to tackle this underestimated health challenge."
 
"This project brings together the expertise of our people with our leading industrial know-how and illustrates our commitment to manufacturing excellence solutions," said Philippe Luscan, executive vice president, global industrial affairs, Sanofi. "Our investment underlines Sanofi's intent to strengthen our industrial capacities in France as a major centre of influenza vaccines production for worldwide markets."
 
The new Val de Reuil facility will be the only site of its kind in France and Sanofi Pasteur remains the sole influenza vaccine producer in the country.  

The Val de Reuil manufacturing site is among world leaders in influenza vaccine production. It was founded in 1973 in the Normandy Region of France, 100 km northwest of Paris. It covers all the steps involved in manufacturing a vaccine: antigen production, formulation, stages of pharmaceutical preparation (filling, inspection and packaging) and quality control. The site also includes Sanofi Pasteur's global vaccine distribution center and ships around 900 million vaccine doses worldwide each year.

VaxigripTetra is a four-strain influenza vaccine, containing two A strains (A/H1N1 and A/H3N2) and two B strains (B/Victoria and B/Yamagata) of influenza virus, as per WHO recommendation. VaxigripTetra is indicated for adults and children from 3 years and older. It is a recent addition to Sanofi Pasteur portfolio of influenza vaccines. Vaxigrip Tetra® is already available in 20 European markets and additional launches around the world are planned in the years ahead.

According to the WHO's estimates, the influenza annual global attack rates are estimated at 5-10% in adults and 20-30% in children. Worldwide, annual influenza epidemics result in three to five million cases of severe illness, and 250,000 to 500,000 deaths.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
IPJPI_150x60en_2017
acssymposium
CPhI-WWW-150x60-stat-v1
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |